|
1
|
Toschi L, Finocchiaro G, Bartolini S,
Gioia V and Cappuzzo F: Role of gemcitabine in cancer therapy.
Future Oncol. 1:7–17. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aapro MS, Martin C and Hatty S:
Gemcitabine-a safety review. Anticancer Drugs. 9:191–201. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tonato M, Mosconi AM and Martin C: Safety
profile of gemcitabine. Anticancer Drugs. 6 Suppl 6:S27–S32. 1995.
View Article : Google Scholar
|
|
4
|
Wong A, Soo RA, Yong WP and Innocenti F:
Clinical pharmacology and pharmacogenetics of gemcitabine. Drug
Metab Rev. 41:77–88. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Moorsel CJ, Pinedo HM, Veerman G,
Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ and Peters
GJ: Mechanisms of synergism between cisplatin and gemcitabine in
ovarian and non-small-cell lung cancer cell lines. Br J Cancer.
80:981–990. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shord SS, Faucette SR, Gillenwater HH,
Pescatore SL, Hawke RL, Socinski MA and Lindley C: Gemcitabine
pharmacokinetics and interaction with paclitaxel in patients with
advanced non-small-cell lung cancer. Cancer Chemother Pharmacol.
51:328–336. 2003.PubMed/NCBI
|
|
7
|
Jiang X, Galettis P, Links M, Mitchell PL
and McLachlan AJ: Population pharmacokinetics of gemcitabine and
its metabolite in patients with cancer: Effect of oxaliplatin and
infusion rate. Br J Clin Pharmacol. 65:326–333. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Teusink AC and Hall PD: Toxicities of
gemcitabine in patients with severe hepatic dysfunction. Ann
Pharmacother. 44:750–754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Felici A, Di Segni S, Milella M,
Colantonio S, Sperduti I, Nuvoli B, Contestabile M, Sacconi A,
Zaratti M, Citro G and Cognetti F: Pharmacokinetics of gemcitabine
at fixed-dose rate infusion in patients with normal and impaired
hepatic function. Clin Pharmacokinet. 48:131–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ciccolini J, Serdjebi C, Peters GJ and
Giovannetti E: Pharmacokinetics and pharmacogenetics of gemcitabine
as a mainstay in adult and pediatric oncology: An EORTC-PAMM
perspective. Cancer Chemother Pharmacol. 78:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Demontis S, Terao M, Brivio M, Zanotta S,
Bruschi M and Garattini E: Isolation and characterization of the
gene coding for human cytidine deaminase. Biochim Biophys Acta.
1443:323–333. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gilbert JA, Salavaggione OE, Ji Y,
Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM and Weinshilboum
RM: Gemcitabine pharmacogenomics: Cytidine deaminase and
deoxycytidylate deaminase gene resequencing and functional
genomics. Clin Cancer Res. 12:1794–1803. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kocabas NA, Aksoy P, Pelleymounter LL,
Moon I, Ryu JS, Gilbert JA, Salavaggione OE, Eckloff BW, Wieben ED,
Yee V, et al: Gemcitabine pharmacogenomics: Deoxycytidine kinase
and cytidylate kinase gene resequencing and functional genomics.
Drug Metab Dispos. 36:1951–1959. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu J, Zhou Y, Zhang J, Chen Y, Zhuang R,
Liu T and Cai W: High incidence of severe neutropenia after
gemcitabine-based chemotherapy in Chinese cancer patients with CDA
79A>C mutation. Clin Chim Acta. 413:1284–1287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Micozzi D, Carpi FM, Pucciarelli S,
Polzonetti V, Polidori P, Vilar S, Williams B, Costanzi S and
Vincenzetti S: Human cytidine deaminase: A biochemical
characterization of its naturally occurring variants. Int J Biol
Macromol. 63:64–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Serdjebi C, Milano G and Ciccolini J: Role
of cytidine deaminase in toxicity and efficacy of nucleosidic
analogs. Expert Opin Drug Metab Toxicol. 11:665–672. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoon KA, Woo SM, Hong EK, Jung MK, Park
WS, Bae K, Han SS, Kim TH, Koh YH, Park SJ and Lee WJ: Cytidine
deaminase as a molecular predictor of gemcitabine response in
patients with biliary tract cancer. Oncology. 89:345–350. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Evrard A and Mbatchi L: Genetic
polymorphisms of drug metabolizing enzymes and transporters: The
long way from bench to bedside. Curr Top Med Chem. 12:1720–1729.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Joerger M, Burgers SA, Baas P, Smit EF,
Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A and Huitema
AD: Germline polymorphisms in patients with advanced nonsmall cell
lung cancer receiving first-line platinum-gemcitabine chemotherapy:
A prospective clinical study. Cancer. 118:2466–2475. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tanaka M, Javle M, Dong X, Eng C,
Abbruzzese JL and Li D: Gemcitabine metabolic and transporter gene
polymorphisms are associated with drug toxicity and efficacy in
patients with locally advanced pancreatic cancer. Cancer.
116:5325–5335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tibaldi C, Giovannetti E, Vasile E, Mey V,
Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C,
Ricciardi S, et al: Correlation of CDA ERCC1, and XPD polymorphisms
with response and survival in gemcitabine/cisplatin-treated
advanced non-small cell lung cancer patients. Clin Cancer Res.
14:1797–1803. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Farrell JJ, Bae K, Wong J, Guha C, Dicker
AP and Elsaleh H: Cytidine deaminase single-nucleotide polymorphism
is predictive of toxicity from gemcitabine in patients with
pancreatic cancer: RTOG 9704. Pharmacogenomics J. 12:395–403. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yomemori K, Ueno H, Okusaka T, Yamamoto N,
Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, et al:
Severe drug toxicity associated with a single-nucleotide
polymorphism of the cytidine deaminase gene in a Japanes cancer
patient treated with gemcytabine plus cisplatin. Clin Cancer Res.
11:2620–2624. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sugiyama E, Kaniwa N, Kim SR,
Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada
J, Kamatani N, et al: Pharmacokinetics of gemcitabine in Japanese
cancer patients: The impact of a cytidine deaminase polymorphism. J
Clin Oncol. 25:32–42. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ludovini V, Floriani I, Pistola L, Minotti
V, Meacci M, Chiari R, Garavaglia D, Tofanetti FR, Flacco A,
Siggillino A, et al: Association of cytidine deaminase and
xeroderma pigmentosum group D polymorphisms with response,
toxicity, and survival in cisplatin/gemcitabine-treated advanced
non-small cell lung cancer patients. J Thorac Oncol. 6:2018–2026.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Okazaki T, Javle M, Tanaka M, Abbruzzese
JL and Li D: Single nucleotide polymorphisms of gemcitabine
metabolic genes and pancreatic cancer survival and drug toxicity.
Clin Cancer Res. 16:320–329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ciccolini J, Dahan L, André N, Evrard A,
Duluc M, Blesius A, Yang C, Giacometti S, Brunet C, Raynal C, et
al: Cytidine deaminase residual activity in serum is a predictive
marker of early severe toxicities in adults after gemcitabine-based
chemotherapies. J Clin Oncol. 28:160–165. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mercier C, Raynal C, Dahan L, Ortiz A,
Evrard A, Dupuis C, Blesius A, Duluc M, Franceschini F, Giacometti
S, et al: Toxic death case in a patient undergoing
gemcitabine-based chemotherapy in relation with cytidine deaminase
downregulation. Pharmacogenet Genomics. 17:841–844. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ding X, Chen W, Fan H and Zhu B: Cytidine
deaminase polymorphism predicts toxicity of gemcitabine-based
chemotherapy. Gene. 559:31–37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou M, Ding YJ, Feng Y, Zhang QR, Xiang Y
and Wan HY: Association of xeroderma pigmentosum group D
(Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr)
polymorphisms with outcome in Chinese non-small cell lung cancer
patients treated with cisplatin-gemcitabine. Genet Mol Res.
13:3310–3318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li H and Wang X and Wang X: The impact of
CDA A79C gene polymorphisms on the response and hematologic
toxicity in gemcitabine-treated patients: A meta-analysis. Int J
Biol Markers. 29:e224–e232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Naranjo CA, Busto U, Sellers EM, Sandor P,
Ruiz I, Roberts EA, Janecek E, Domecq C and Greenblatt DJ: A method
for estimating the probability of adverse drug reactions. Clin
Pharmacol Ther. 30:239–245. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Waseem M, Bhardwaj M, Tabassum H,
Raisuddin S and Parvez S: Cisplatin hepatotoxicity mediated by
mitochondrial stress. Drug Chem Toxicol. 38:452–459. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu Y and Cederbaum AI: Cisplatin-induced
hepatotoxicity is enhanced by elevated expression of cytochrome
P450 2E1. Toxicol Sci. 89:515–523. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Karale S and Kamath JV: Effect of daidzein
on cisplatin-induced hematotoxicity and hepatotoxicity in
experimental rats. Indian J Pharmacol. 49:49–54. 2017.PubMed/NCBI
|
|
37
|
Naziroglu M, Karaoğlu A and Aksoy AO:
Selenium and high dose vitamin E administration protects
cisplatin-induced oxidative damage to renal, liver and lens tissues
in rats. Toxicology. 195:221–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
dos Santos NA, Martins NM, Curti C, Pires
Bianchi Mde L and dos Santos AC: Dimethylthiourea protects against
mitochondrial oxidative damage induced by cisplatin in liver of
rats. Chem Biol Interact. 170:177–186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Raynal C, Ciccolini J, Mercier C, Boyer
JC, Polge A, Lallemant B, Mouzat K, Lumbroso S, Brouillet JP and
Evrard A: High-resolution melting analysis of sequence variations
in the cytidine deaminase gene (CDA) in patients with cancer
treated with gemcitabine. Ther Drug Monit. 32:53–60. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Petros WP and Evans WE: Pharmacogenomics
in cancer therapy: Is host genome variability important? Trends
Pharmacol Sci. 25:457–464. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Evrard A, Lacarelle B and Ciccolini J:
Severe or lethal toxicities with nucleosidic analogs: Time for
action. Pharmacogenomics. 14:227–230. 2013. View Article : Google Scholar : PubMed/NCBI
|
